This appears to act via activation of c-Fos and AP-1 expression (39)
With the increased popularity of glucagon-like-peptide-1 (GLP-1) receptor agonist medications, educating clinicians on where people are going for these medications, how they are prescribed, and the potential side effects is important
Armored CAR-T cells and bispecific T-cell engagers are now being combined with vascular or stromal-targeting agents, with early 20242025 trials reporting encouraging activity in selected solid tumors previously considered refractory to cellular immunotherapy (199, 200)
5.1, we first consider dietary modulation as the foundational, patient-centered lever for long-term ecosystem steering
With SGLT2 inhibitors established as the cornerstone pharmacotherapy for DKD, careful evaluation of potential nutrient-drug interactions accompanying high-dose polyphenolic supplementation becomes imperative